Proprietary technology positioned to become the new standard of care in global drug delivery
SANTA CLARA, California, Oct. 2, 2018 /PRNewswire/ -- Based on its recent analysis of the global drug delivery systems market, Frost & Sullivan recognizes PharmaJet with the 2018 Global Technology Innovation Award for an innovative jet injection technology offering a needle-free, accurate, and consistent method of vaccine delivery. The company's versatile and proven needle-free devices support both established vaccines and novel pharmaceuticals for intramuscular, subcutaneous, and intradermal drug delivery.
Click Here to read the full Award Write Up.
PharmaJet's portfolio consists of:
- Stratis® IM/SC (Stratis®) for intramuscular or subcutaneous delivery
- Tropis® ID (Tropis®) for intradermal delivery of liquid medicines directly into the skin
The device uses a simple point-and-click technique to calibrate to a specific vaccine volume, which helps minimize vaccine wastage. The spring-powered needle-free injector uses a narrow stream of fluid that goes through the skin in about 1/10th of a second. As the device does not touch the patient and uses single-use syringes, it eliminates the risk of reuse and contamination.
"PharmaJet designed its jet injection devices to withstand the rigors of bush medicine, as demonstrated by the World Health Organization's (WHO) successful clinical trials for Tropis in countries such as Cambodia, The Gambia, Cuba, and Pakistan," said Patrick Riley, Principal Analyst at Frost & Sullivan. "Unlike competing needle-free injectors designed for a single application, PharmaJet's technology addresses an entire portfolio of vaccines and drugs. The devices are currently being used to deliver vaccines for, influenza, polio, measles, mumps, and rubella, and there are over 60 studies complete or in process across indications including Zika, Dengue, Malaria, HPV, and others."
PharmaJet also provides customers with total cost savings of up to 40 percent. Even though its products are more expensive than prefilled syringes, they do not require costly needle disposal and lengthy injection training. Furthermore, the syringes can extract more doses out of a vaccine vial because caregivers do not have to overfill syringes to compensate for the inaccuracy inherent in traditional needle syringes.
Significantly, PharmaJet's is the only WHO pre-qualified needle-free injection system and has market clearance from global regulatory bodies such as the FDA, CE, DCGI, and ANVISA. Both patients and providers have responded favorably to the innovative technology, while the company's Web-accessible and comprehensive training program further boosts its value proposition.
"Encouraged by the success of Tropis in the novel pharmaceutical space, PharmaJet stepped up collaboration efforts with several therapeutic cancer vaccine developers. Its other areas of interest include nucleic acid vaccine development programs and expanding the use of its device in the global influenza market," noted Riley. "With unparalleled ease-of-use and revolutionary technology that ensures proper dosing, the company can deliver more potency than a needle and syringe with less vaccine — positioning it to become the new standard of care."
Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
Based in Golden, Colorado, PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. The innovative Stratis® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016 and WHO PQS certification in June 2018. The PharmaJet Needle-free Injectors are safe, fast and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.
P: 1-888-900-4321 Option 3
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.
SOURCE Frost & Sullivan